More than seven months have passed since MSD Korea’s application for expanding coverage for 13 indications of Keytruda (pembrolizumab) was stuck in the Cancer Disease Review Committee (CDRC), prompting anxious patients to request the review of individual indications.Contrary to MSD Korea's intention
GI Cell, an affiliate of GI Innovation, has submitted an application to the Ministry of Food and Drug Safety for phase 1/2a clinical trials to evaluate the safety and efficacy of a combination therapy between GI Cell's allogeneic NK cell therapy, T.O.P. NK and GI-101A, in patients with recurrent and
Hanmi Pharm reported a groundbreaking performance for 2023, with consolidated sales and operating profit reaching 1.49 trillion won ($1.1 billion) and 220.7 billion won, up 11.97 percent and 39.5 percent from the previous year, thanks to royalties and strong domestic sales.The company also reported
LG Chem's life sciences business has hit a milestone by exceeding 1 trillion won ($755.8 million) in annual sales for the first time in the company's history. The performance was backed by strong sales from AVEO Oncology, a U.S. subsidiary acquired in April 2023. The sales represent a 30.1 percent g
Meta Fines, a drug repositioning company, said Thursday that it has signed a licensing-out agreement with BMI Korea for its cancer cachexia drug ASCA101_CC.Under the agreement, BMI Korea will co-own the global technology transfer rights of ASCA101_CC with Meta Fines and will have the right to licens
Sanofi Korea launched Aprovasc Tab, the first antihypertensive combination drug comprising irbesartan and amlodipine besylate co-developed with Handok on Thursday.Aprovasc won approval from the Ministry of Food and Drug Safety in November 2023 for treating essential hypertension in patients whose bl
Hanmi Pharma said it has signed a strategic agreement with its U.S. partner company, Assertio Holdings, which previously acquired Spectrum Pharmaceuticals, to re-acquire the rights to Rolontis, a long-acting neutropenia treatment and Korea's 33rd novel drug, for the Asian and African markets.Rolonti
Takeda Korea said the National Health Insurance will reimburse its adult acquired hemophilia A (AHA) treatment Objzur Inj (susoctocog alpha) starting Thursday.Obizur is Korea's only blood clotting factor VIII treatment for adult AHA. It won the Ministry of Food and Drug Safety approval in March last
BNC Korea said Thursday that it has signed a joint research and development agreement with SML Biopharm to develop a GLP1 agonist for treating diabetes and obesity using mRNA technology.Under the agreement, SML Biopharm will utilize its mRNA platform expression technology to express target genes in
Ildong Pharmaceutical has received material patents in China and Japan for its metabolic disease drug candidate, ID110521156, which is being developed through its subsidiary Yunovia.ID110521156 is the GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist) family of drugs and acts as an an
Pfizer Korea and Hanlim MS said they entered into a co-marketing agreement for the drug Xeljanz (ingredient: tofacitinib citrate), a drug used in the treatment of various autoimmune diseases.This collaboration aims to expand the availability and benefits of Xeljanz to a wider patient demographic thr
CHA Vaccine Institute, a subsidiary of CHA Biotech, has disclosed the top-line results from the phase 1 clinical trial of its third-generation hepatitis B vaccine candidate, CVI-HBV-002, which showed that the candidate had higher efficacy compared to currently available vaccines. The announcement pr
CG Bio, a regenerative medicine company, said Wednesday that it has launched Easydew MD cream 200g, which strengthens the skin barrier.The skin barrier is the outer layer of the skin that protects the skin from external threats such as infectious agents, chemicals, systemic toxins, and allergens.Eas
AstraZeneca Korea said Wednesday that it has signed an agreement with HK inno.N, a Kosdaq-listed healthcare company, to co-promote Forxiga's combination drugs, Xigduo XR (dapagliflozin + metformin) and Sidapvia Tab (dapagliflozin + sitagliptin), and to distribute Forxiga (dapagliflozin) in Korea.Und
Celltrion held an orientation for biotech startup companies selected through the Seoul Biohub-Celltrion Open Innovation Program on Tuesday at its Global Biotechnology Research Center in Songdo, Incheon.The Seoul Biohub-Celltrion Open Innovation Program fosters and supports biotech and medical startu
Boehringer Ingelheim Korea said it has commenced a voluntary recall of select batches for Spiriva Respimat (ingredient: tiotropium bromide hydrate), its chronic obstructive pulmonary disease (COPD) and asthma medication.This medication is approved for use as a bronchodilator in the maintenance treat
In a recent media session organized by MSD Korea, a local professor shared insights regarding the efficacy of MSD's Lagevrio (ingredient: molnupiravir) in treating Covid-19, with a particular focus on high-risk groups.As the global community continues to recover from the pandemic, the Covid-19 virus
Bayer Korea's treatment for chronic kidney disease with type 2 diabetes, Kerendia (finerenone), will be covered by health insurance for adult patients starting next month.Kerendia is a first-in-class non-steroidal selective antagonist of the mineralocorticoid receptor, a novel mechanism of action th
Dong-A Pharmaceutical said Tuesday that it has launched a seven-day supply of Orthomol Vital M (for men) and Orthomol Vital F (for women), premium vitamin supplements from German nutraceutical company Orthomol.Orthomol Vital is a nutraceutical brand officially imported and sold in Korea by Dong-A Ph
For the sustainable growth of the domestic biopharmaceutical industry, the government must reform regulations to facilitate businesses’ investment, an industry leader said on Tuesday.To this end, the design of a simple, clear, and predictable drug price system is essential, and the legal status of t
